New diabetes clinical trial: The T1D Exchange Registry | | |
New diabetes clinical trial: In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part B | | |
New diabetes clinical trial: Meta-analysis of Oats for Diabetes Prevention and Management | | |
New diabetes clinical trial: The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. | | |
New diabetes clinical trial: Effectiveness of Health Management of Glycemic Control and Physical Activity in Type 2 Diabetes Mellitus Using Smartphone Application | | |
New diabetes clinical trial: The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication | | |
New diabetes clinical trial: Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone | | |
New diabetes clinical trial: Bialystok Exercise Study in Diabetes | | |
New diabetes clinical trial: The Severity of COVID 19 in Diabetes and Non-diabetes Patients | | |
New diabetes clinical trial: Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes | | |
New diabetes clinical trial: Effects of Probiotics and Fibers on Albuminuria in Persons With Type 1 Diabetes | | |
New diabetes clinical trial: Postbiotic MBS and Metformin Combination in Patients With T2DM | | |
New diabetes clinical trial: Comparasion of the Immediate Effect of Myofascial Relaxation Technique and Kinesiology Taping | | |
New diabetes clinical trial: Combined Active Treatment in Type 2 Diabetes With NASH | | Published on: November 20, 2020 at 07:00PM Conditions: Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD) Interventions: Drug: Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector; Drug: Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide; Drug: Placebo matching empagliflozin and placebo pen injector matching semaglutide Sponsors: The Deutsche Diabetes Forschungsgesellschaft e.V.; Boehringer Ingelheim; German Center for Diabetes Research; Federal Ministry of Health, Germany; Ministry of Innovation, Science and Research in North Rhine-Westphalia; Novo Nordisk A/S Not yet recruiting https://clinicaltrials.gov/ct2/show/NCT04639414?term=diabetes&sfpd_d=14 November 20, 2020 at 02:24PM via ClinicalTrials.gov |
Няма коментари:
Публикуване на коментар